Tango Therapeutics Inc
TNGXHealthcare|Biotechnology|USA
$31.06
+0.52 (+1.71%)
Tangible Book
$2.72
Upcoming Data Readouts (3)
Mar 2027
Est. completion
P1P2Non Small Cell Lung Cancer
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544n=191
May 2027
Est. completion
P1P2MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
NCT06188702n=60
Jun 2027
Est. completion
P1P2PDAC
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591n=183
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.